AnalystBook Research · Company Intelligence

Joint Stock Co Kaspi.kz

KSPINasdaq

Built from Joint Stock Co Kaspi.kz's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Revenue rose 59.8% to KZT 4046.07B after Kaspi took control of Türkiye's Hepsiburada, but net income rose only 3.2% as Türkiye lost money and margins fell.

The read at a glance✓ Audited against SEC data
  • Growth — Revenue +59.8% to KZT 4046.07B, including HepsiburadaOK
  • Profitability — Net income +3.2%; net margin down 1454 bps to 26.5%Watch
  • Cash — Free cash flow KZT 491.10B, +1.0%; capital expenditure +90.7%Note
  • Balance sheet — Total equity +64.2% to KZT 2491.84BOK
  • Türkiye — New Türkiye business: net loss in 2025Watch
  • Users — 27.5 million users: 15.7m Kazakhstan, 11.8m TürkiyeOK

Business

Kaspi.kz runs a super app in Kazakhstan that combines payments, an online marketplace and fintech services for consumers and merchants. In 2025 it acquired a controlling stake in Hepsiburada, a leading e-commerce platform in Türkiye. It reports in Kazakh tenge.

Latest filings

  • 6-K · Company announcement (foreign filer)2026-09-10
  • 6-K · Company announcement (foreign filer)2026-08-12
  • 6-K · Company announcement (foreign filer)2026-08-10
  • 6-K · Company announcement (foreign filer)2026-06-12
  • 6-K · Company announcement (foreign filer)2026-05-14
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Joint Stock Co Kaspi.kz, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.